LINC01089

Summary

LINC01089 (long intergenic non-protein coding RNA 1089, HGNC:27886) is a long non-coding RNA gene on chromosome 12q24.31.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27886
Approved symbol	LINC01089
Name	long intergenic non-protein coding RNA 1089
Location	12q24.31
Locus type	RNA, long non-coding
Status	Approved
Aliases	LIMT, AK096174
Ensembl gene	ENSG00000212694
Ensembl biotype	lncRNA
Entrez	338799
RNAcentral	URS0000CCE02F — lncRNA, 999 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 12 lncRNA

ENST00000428029, ENST00000429892, ENST00000535614, ENST00000535643, ENST00000536662, ENST00000537157, ENST00000538335, ENST00000541694, ENST00000542933, ENST00000543167, ENST00000543334, ENST00000545885

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000428029 — 5 exons

Exon	Start	End
ENSE00001643548	121802631	121802784
ENSE00001689543	121802879	121802933
ENSE00001783682	121795640	121796242
ENSE00003488580	121801707	121801808
ENSE00003506483	121799847	121799956

Expression profiles

Bgee: expression breadth ubiquitous, 191 present calls, max score 96.70.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.6420 / max 614.8629, expressed in 1771 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
133773	16.1008	1744
133768	1.5623	322
133775	1.2041	698
133764	0.6030	347
133769	0.4908	161
133770	0.4302	153
133774	0.3607	199
133767	0.3454	120
133771	0.2250	81
133772	0.2159	87

Top tissues by expression

234 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of thyroid gland	UBERON:0001119	96.70	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.67	gold quality
right uterine tube	UBERON:0001302	96.61	gold quality
cerebellar hemisphere	UBERON:0002245	96.58	gold quality
cerebellar cortex	UBERON:0002129	96.41	gold quality
left lobe of thyroid gland	UBERON:0001120	95.78	gold quality
endocervix	UBERON:0000458	95.43	gold quality
metanephros cortex	UBERON:0010533	95.09	gold quality
cerebellum	UBERON:0002037	94.93	gold quality
right coronary artery	UBERON:0001625	94.82	gold quality
left ovary	UBERON:0002119	94.53	gold quality
thyroid gland	UBERON:0002046	94.49	gold quality
body of uterus	UBERON:0009853	94.35	gold quality
right ovary	UBERON:0002118	94.18	gold quality
minor salivary gland	UBERON:0001830	93.77	gold quality
ganglionic eminence	UBERON:0004023	93.52	gold quality
small intestine Peyer’s patch	UBERON:0003454	93.49	gold quality
ectocervix	UBERON:0012249	93.38	gold quality
ascending aorta	UBERON:0001496	93.29	gold quality
spleen	UBERON:0002106	93.26	gold quality
tibial nerve	UBERON:0001323	93.25	gold quality
thoracic aorta	UBERON:0001515	93.20	gold quality
adenohypophysis	UBERON:0002196	92.95	gold quality
pituitary gland	UBERON:0000007	92.84	gold quality
descending thoracic aorta	UBERON:0002345	92.71	gold quality
transverse colon	UBERON:0001157	92.59	gold quality
aorta	UBERON:0000947	92.58	gold quality
left coronary artery	UBERON:0001626	92.28	gold quality
popliteal artery	UBERON:0002250	92.28	gold quality
tibial artery	UBERON:0007610	92.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.18

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 8)

• Interestingly, EGF rapidly downregulates LINC01089 (here renamed LncRNA Inhibiting Metastasis; LIMT) expression by enhancing histone deacetylation at the respective promoter. (PMID:27485121)
• Glioma tissues exhibit loss of LINC01089 (LncRNA001089) expression, which is associated with poor prognosis in glioma patients. (PMID:30868865)
• LINC01089 inhibits the progression of cervical cancer via inhibiting miR-27a-3p and increasing BTG2. (PMID:33025678)
• LncRNA-LINC01089 inhibits lung adenocarcinoma cell proliferation and promotes apoptosis via sponging miR-543. (PMID:33892399)
• LINC01089 suppresses lung adenocarcinoma cell proliferation and migration via miR-301b-3p/STARD13 axis. (PMID:34281560)
• LINC01089, suppressed by YY1, inhibits lung cancer progression by targeting miR-301b-3p/HPDG axis. (PMID:34561789)
• The crosstalk between LINC01089 and hippo pathway inhibits osteosarcoma progression. (PMID:36399257)
• Super Enhancer-Regulated LncRNA LINC01089 Induces Alternative Splicing of DIAPH3 to Drive Hepatocellular Carcinoma Metastasis. (PMID:37756562)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.